ABEONA THERAPEUTICS INC (ABEO) Fundamental Analysis & Valuation

NASDAQ:ABEO • US00289Y2063

Current stock price

5.335 USD
0 (-0.09%)
Last:

This ABEO fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

3

1. ABEO Profitability Analysis

1.1 Basic Checks

  • ABEO had negative earnings in the past year.
  • In the past year ABEO has reported a negative cash flow from operations.
  • In the past 5 years ABEO reported 4 times negative net income.
  • In the past 5 years ABEO always reported negative operating cash flow.
ABEO Yearly Net Income VS EBIT VS OCF VS FCFABEO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M

1.2 Ratios

  • ABEO's Return On Assets of 32.42% is amongst the best of the industry. ABEO outperforms 97.48% of its industry peers.
  • Looking at the Return On Equity, with a value of 44.71%, ABEO belongs to the top of the industry, outperforming 98.06% of the companies in the same industry.
Industry RankSector Rank
ROA 32.42%
ROE 44.71%
ROIC N/A
ROA(3y)-36.92%
ROA(5y)-57.04%
ROE(3y)-155.18%
ROE(5y)-158.6%
ROIC(3y)N/A
ROIC(5y)N/A
ABEO Yearly ROA, ROE, ROICABEO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100 -200 -300

1.3 Margins

  • ABEO's Profit Margin of 1223.08% is amongst the best of the industry. ABEO outperforms 99.81% of its industry peers.
  • ABEO's Gross Margin of 73.68% is amongst the best of the industry. ABEO outperforms 81.17% of its industry peers.
Industry RankSector Rank
OM N/A
PM (TTM) 1223.08%
GM 73.68%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ABEO Yearly Profit, Operating, Gross MarginsABEO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 1K -1K -2K -3K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. ABEO Health Analysis

2.1 Basic Checks

  • ABEO does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, ABEO has more shares outstanding
  • ABEO has more shares outstanding than it did 5 years ago.
  • ABEO has a better debt/assets ratio than last year.
ABEO Yearly Shares OutstandingABEO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M
ABEO Yearly Total Debt VS Total AssetsABEO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M

2.2 Solvency

  • Based on the Altman-Z score of -2.06, we must say that ABEO is in the distress zone and has some risk of bankruptcy.
  • ABEO has a Altman-Z score (-2.06) which is in line with its industry peers.
  • ABEO has a Debt/Equity ratio of 0.05. This is a healthy value indicating a solid balance between debt and equity.
  • Looking at the Debt to Equity ratio, with a value of 0.05, ABEO is in line with its industry, outperforming 40.58% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Altman-Z -2.06
ROIC/WACCN/A
WACC9.32%
ABEO Yearly LT Debt VS Equity VS FCFABEO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M 100M 150M

2.3 Liquidity

  • ABEO has a Current Ratio of 6.93. This indicates that ABEO is financially healthy and has no problem in meeting its short term obligations.
  • ABEO's Current ratio of 6.93 is fine compared to the rest of the industry. ABEO outperforms 66.41% of its industry peers.
  • ABEO has a Quick Ratio of 6.74. This indicates that ABEO is financially healthy and has no problem in meeting its short term obligations.
  • ABEO has a better Quick ratio (6.74) than 65.83% of its industry peers.
Industry RankSector Rank
Current Ratio 6.93
Quick Ratio 6.74
ABEO Yearly Current Assets VS Current LiabilitesABEO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. ABEO Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 28.74% over the past year.
  • ABEO shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -10.26% yearly.
EPS 1Y (TTM)28.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-164.29%
Revenue 1Y (TTM)N/A
Revenue growth 3Y60.41%
Revenue growth 5Y-10.26%
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 33.17% on average over the next years. This is a very strong growth
  • ABEO is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 128.94% yearly.
EPS Next Y33.49%
EPS Next 2Y46.92%
EPS Next 3Y45.48%
EPS Next 5Y33.17%
Revenue Next Year1031.31%
Revenue Next 2Y426.92%
Revenue Next 3Y250.93%
Revenue Next 5Y128.94%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ABEO Yearly Revenue VS EstimatesABEO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 100M 200M 300M 400M
ABEO Yearly EPS VS EstimatesABEO Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 -10 -20 -30

More info and screens

Find the best growth stocksShow best growing peers

1

4. ABEO Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ABEO. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ABEO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ABEO Price Earnings VS Forward Price EarningsABEO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ABEO Per share dataABEO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

  • ABEO's earnings are expected to grow with 45.48% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y46.92%
EPS Next 3Y45.48%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ABEO Dividend Analysis

5.1 Amount

  • No dividends for ABEO!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ABEO Fundamentals: All Metrics, Ratios and Statistics

ABEONA THERAPEUTICS INC

NASDAQ:ABEO (4/28/2026, 1:05:58 PM)

5.335

0 (-0.09%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-17
Earnings (Next)05-20
Inst Owners66.62%
Inst Owner Change-0.03%
Ins Owners6.64%
Ins Owner Change12.46%
Market Cap304.36M
Revenue(TTM)5.82M
Net Income(TTM)71.18M
Analysts86.67
Price Target19.96 (274.13%)
Short Float %35.9%
Short Ratio13.68
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)32.11%
Min EPS beat(2)-1.98%
Max EPS beat(2)66.19%
EPS beat(4)2
Avg EPS beat(4)15.87%
Min EPS beat(4)-36.14%
Max EPS beat(4)66.19%
EPS beat(8)4
Avg EPS beat(8)12.07%
EPS beat(12)6
Avg EPS beat(12)1.89%
EPS beat(16)8
Avg EPS beat(16)17.9%
Revenue beat(2)1
Avg Revenue beat(2)-49.59%
Min Revenue beat(2)-100%
Max Revenue beat(2)0.82%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-5.19%
PT rev (3m)-5.19%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-178.99%
EPS NY rev (1m)-1186.3%
EPS NY rev (3m)-1429.64%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-75.51%
Revenue NY rev (1m)-18.33%
Revenue NY rev (3m)-42.77%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 52.3
P/FCF N/A
P/OCF N/A
P/B 1.91
P/tB 1.91
EV/EBITDA N/A
EPS(TTM)-1.24
EYN/A
EPS(NY)-0.82
Fwd EYN/A
FCF(TTM)-1.48
FCFYN/A
OCF(TTM)-1.34
OCFYN/A
SpS0.1
BVpS2.79
TBVpS2.79
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA 32.42%
ROE 44.71%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 1223.08%
GM 73.68%
FCFM N/A
ROA(3y)-36.92%
ROA(5y)-57.04%
ROE(3y)-155.18%
ROE(5y)-158.6%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 312.87%
Cap/Sales 137.03%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.93
Quick Ratio 6.74
Altman-Z -2.06
F-Score6
WACC9.32%
ROIC/WACCN/A
Cap/Depr(3y)149.8%
Cap/Depr(5y)116.26%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)28.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-164.29%
EPS Next Y33.49%
EPS Next 2Y46.92%
EPS Next 3Y45.48%
EPS Next 5Y33.17%
Revenue 1Y (TTM)N/A
Revenue growth 3Y60.41%
Revenue growth 5Y-10.26%
Sales Q2Q%N/A
Revenue Next Year1031.31%
Revenue Next 2Y426.92%
Revenue Next 3Y250.93%
Revenue Next 5Y128.94%
EBIT growth 1Y-39.3%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-44.2%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-36.26%
OCF growth 3YN/A
OCF growth 5YN/A

ABEONA THERAPEUTICS INC / ABEO Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for ABEONA THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 3 / 10 to ABEO.


Can you provide the valuation status for ABEONA THERAPEUTICS INC?

ChartMill assigns a valuation rating of 1 / 10 to ABEONA THERAPEUTICS INC (ABEO). This can be considered as Overvalued.


What is the profitability of ABEO stock?

ABEONA THERAPEUTICS INC (ABEO) has a profitability rating of 3 / 10.


What is the financial health of ABEONA THERAPEUTICS INC (ABEO) stock?

The financial health rating of ABEONA THERAPEUTICS INC (ABEO) is 4 / 10.